Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 19 Sept 2026, 12:04 am
Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio Cohance Lifesciences has remitted USD 10 million via internal accruals to subscribe to 188,680 Compulsorily Convertible Preferred Stocks (CCPS) of its US-based subsidiary, NJ Bio Inc., at USD 53.00 per share. The CCPS are convertible into equity after 3 years, with completion expected before the end of Sep'26. The capital infusion will fund growth initiatives and capex in NJ Bio's antibody-drug conjugate (ADC) CRDMO business. NJ Bio posted revenues of USD 20.6 million in CY23, USD 32.6 million in CY24, and USD 23.5 million in CY25.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
